Ingalls & Snyder LLC Grows Stock Position in Pfizer Inc. $PFE

Ingalls & Snyder LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 7.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755,313 shares of the biopharmaceutical company’s stock after buying an additional 51,993 shares during the quarter. Ingalls & Snyder LLC’s holdings in Pfizer were worth $18,309,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC boosted its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in Pfizer in the 2nd quarter valued at approximately $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.13.

Pfizer Price Performance

PFE stock opened at $24.79 on Friday. The stock has a 50-day moving average price of $24.87 and a two-hundred day moving average price of $24.18. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.17. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $140.92 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.